Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer

Is There an Optimal Treatment Sequence?

Stéphane Oudard, Pablo Maroto, Gaston Demonty, Winald R. Gerritsen

Research output: Contribution to journalReview article

Abstract

Context Recent developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have led to uncertainty about the optimal sequence of agents. Objective To review and assess treatment options and sequence in patients with mCRPC. Evidence acquisition To identify data on the optimal use of approved treatments, we searched PubMed for studies on the use of recently approved agents for men with mCRPC published before March 2015. Phase 3 and other key studies were included in the review of efficacy and safety. In this review, we offer our critical interpretation of potential treatment sequences for drug use in the light of our clinical experience. Evidence synthesis Since 2004, the treatment landscape for mCRPC has changed dramatically following the approval of docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, denosumab, and radium-223 chloride. To date, only small-scale studies have been undertaken that provide evidence on the sequencing of these treatments. Ideally, randomised, prospective studies would evaluate different sequence options thoroughly so that physicians could make evidence-based decisions, but the number of new agents makes this impractical. When deciding which treatment to prescribe, physicians will need to use the available evidence combined with their own clinical judgement. The potential for cross-resistance between taxanes and hormonal therapies and the possibility that patients might not be suitable for aggressive therapies in later lines should be taken into account. Prevention of complications associated with bone metastases should also be a key consideration because of the major impact these events have on quality of life and healthcare costs. Conclusions The recent approval of numerous new agents has resulted in considerable improvements in outcomes for patients with mCRPC. Further studies determining the optimal treatment algorithm, in addition to open discussion of best practice among physicians, are required to ensure patients obtain the maximum possible benefit from their treatment. Patient summary In recent years a large number of new treatment options have been approved for use in men with prostate cancer. In the absence of clinical trials assessing the use of one option versus another in specific patient groups, it is important to review the currently published evidence to try to understand patients receive the best treatment options in the correct order.

Original languageEnglish (US)
Pages (from-to)426-440
Number of pages15
JournalEuropean Urology Focus
Volume2
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Castration
Prostatic Neoplasms
Therapeutics
docetaxel
Physicians
Taxoids
Radium
Quality of Health Care
Practice Guidelines
PubMed
Health Care Costs
Uncertainty
Chlorides
Quality of Life

Keywords

  • Androgen deprivation therapy
  • Bone metastasis
  • Bone-targeted agent
  • Chemotherapy
  • Immunotherapy
  • Metastatic castration-resistant prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer : Is There an Optimal Treatment Sequence? / Oudard, Stéphane; Maroto, Pablo; Demonty, Gaston; Gerritsen, Winald R.

In: European Urology Focus, Vol. 2, No. 4, 01.10.2016, p. 426-440.

Research output: Contribution to journalReview article

Oudard, Stéphane ; Maroto, Pablo ; Demonty, Gaston ; Gerritsen, Winald R. / Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer : Is There an Optimal Treatment Sequence?. In: European Urology Focus. 2016 ; Vol. 2, No. 4. pp. 426-440.
@article{d3587e5b58634055a45fe42c13e1b919,
title = "Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?",
abstract = "Context Recent developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have led to uncertainty about the optimal sequence of agents. Objective To review and assess treatment options and sequence in patients with mCRPC. Evidence acquisition To identify data on the optimal use of approved treatments, we searched PubMed for studies on the use of recently approved agents for men with mCRPC published before March 2015. Phase 3 and other key studies were included in the review of efficacy and safety. In this review, we offer our critical interpretation of potential treatment sequences for drug use in the light of our clinical experience. Evidence synthesis Since 2004, the treatment landscape for mCRPC has changed dramatically following the approval of docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, denosumab, and radium-223 chloride. To date, only small-scale studies have been undertaken that provide evidence on the sequencing of these treatments. Ideally, randomised, prospective studies would evaluate different sequence options thoroughly so that physicians could make evidence-based decisions, but the number of new agents makes this impractical. When deciding which treatment to prescribe, physicians will need to use the available evidence combined with their own clinical judgement. The potential for cross-resistance between taxanes and hormonal therapies and the possibility that patients might not be suitable for aggressive therapies in later lines should be taken into account. Prevention of complications associated with bone metastases should also be a key consideration because of the major impact these events have on quality of life and healthcare costs. Conclusions The recent approval of numerous new agents has resulted in considerable improvements in outcomes for patients with mCRPC. Further studies determining the optimal treatment algorithm, in addition to open discussion of best practice among physicians, are required to ensure patients obtain the maximum possible benefit from their treatment. Patient summary In recent years a large number of new treatment options have been approved for use in men with prostate cancer. In the absence of clinical trials assessing the use of one option versus another in specific patient groups, it is important to review the currently published evidence to try to understand patients receive the best treatment options in the correct order.",
keywords = "Androgen deprivation therapy, Bone metastasis, Bone-targeted agent, Chemotherapy, Immunotherapy, Metastatic castration-resistant prostate cancer",
author = "St{\'e}phane Oudard and Pablo Maroto and Gaston Demonty and Gerritsen, {Winald R.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.euf.2015.11.008",
language = "English (US)",
volume = "2",
pages = "426--440",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer

T2 - Is There an Optimal Treatment Sequence?

AU - Oudard, Stéphane

AU - Maroto, Pablo

AU - Demonty, Gaston

AU - Gerritsen, Winald R.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Context Recent developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have led to uncertainty about the optimal sequence of agents. Objective To review and assess treatment options and sequence in patients with mCRPC. Evidence acquisition To identify data on the optimal use of approved treatments, we searched PubMed for studies on the use of recently approved agents for men with mCRPC published before March 2015. Phase 3 and other key studies were included in the review of efficacy and safety. In this review, we offer our critical interpretation of potential treatment sequences for drug use in the light of our clinical experience. Evidence synthesis Since 2004, the treatment landscape for mCRPC has changed dramatically following the approval of docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, denosumab, and radium-223 chloride. To date, only small-scale studies have been undertaken that provide evidence on the sequencing of these treatments. Ideally, randomised, prospective studies would evaluate different sequence options thoroughly so that physicians could make evidence-based decisions, but the number of new agents makes this impractical. When deciding which treatment to prescribe, physicians will need to use the available evidence combined with their own clinical judgement. The potential for cross-resistance between taxanes and hormonal therapies and the possibility that patients might not be suitable for aggressive therapies in later lines should be taken into account. Prevention of complications associated with bone metastases should also be a key consideration because of the major impact these events have on quality of life and healthcare costs. Conclusions The recent approval of numerous new agents has resulted in considerable improvements in outcomes for patients with mCRPC. Further studies determining the optimal treatment algorithm, in addition to open discussion of best practice among physicians, are required to ensure patients obtain the maximum possible benefit from their treatment. Patient summary In recent years a large number of new treatment options have been approved for use in men with prostate cancer. In the absence of clinical trials assessing the use of one option versus another in specific patient groups, it is important to review the currently published evidence to try to understand patients receive the best treatment options in the correct order.

AB - Context Recent developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have led to uncertainty about the optimal sequence of agents. Objective To review and assess treatment options and sequence in patients with mCRPC. Evidence acquisition To identify data on the optimal use of approved treatments, we searched PubMed for studies on the use of recently approved agents for men with mCRPC published before March 2015. Phase 3 and other key studies were included in the review of efficacy and safety. In this review, we offer our critical interpretation of potential treatment sequences for drug use in the light of our clinical experience. Evidence synthesis Since 2004, the treatment landscape for mCRPC has changed dramatically following the approval of docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, denosumab, and radium-223 chloride. To date, only small-scale studies have been undertaken that provide evidence on the sequencing of these treatments. Ideally, randomised, prospective studies would evaluate different sequence options thoroughly so that physicians could make evidence-based decisions, but the number of new agents makes this impractical. When deciding which treatment to prescribe, physicians will need to use the available evidence combined with their own clinical judgement. The potential for cross-resistance between taxanes and hormonal therapies and the possibility that patients might not be suitable for aggressive therapies in later lines should be taken into account. Prevention of complications associated with bone metastases should also be a key consideration because of the major impact these events have on quality of life and healthcare costs. Conclusions The recent approval of numerous new agents has resulted in considerable improvements in outcomes for patients with mCRPC. Further studies determining the optimal treatment algorithm, in addition to open discussion of best practice among physicians, are required to ensure patients obtain the maximum possible benefit from their treatment. Patient summary In recent years a large number of new treatment options have been approved for use in men with prostate cancer. In the absence of clinical trials assessing the use of one option versus another in specific patient groups, it is important to review the currently published evidence to try to understand patients receive the best treatment options in the correct order.

KW - Androgen deprivation therapy

KW - Bone metastasis

KW - Bone-targeted agent

KW - Chemotherapy

KW - Immunotherapy

KW - Metastatic castration-resistant prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84995530389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995530389&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2015.11.008

DO - 10.1016/j.euf.2015.11.008

M3 - Review article

VL - 2

SP - 426

EP - 440

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

IS - 4

ER -